Pharsight

Pemfexy patents expiration

PEMFEXY's oppositions filed in EPO
PEMFEXY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7772209 EAGLE PHARMS Antifolate combination therapies
May, 2022

(1 year, 10 months ago)

US11793813 EAGLE PHARMS Pemetrexed formulations
Feb, 2036

(11 years from now)

Pemfexy is owned by Eagle Pharms.

Pemfexy contains Pemetrexed.

Pemfexy has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Pemfexy are:

  • US7772209

Pemfexy was authorised for market use on 08 February, 2020.

Pemfexy is available in solution;intravenous dosage forms.

Pemfexy can be used as use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer.

The generics of Pemfexy are possible to be released after 19 February, 2036.

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administra...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PEMFEXY family patents

Family Patents